Shozo Mori1, Junji Kita2, Masato Kato2, Mitsugi Shimoda2, Keiichi Kubota2. 1. Department of Gastroenterological Surgery, Dokkyo Medical University, 880 Kitakobayashi, Mibu, Shimotsuga, Tochigi 321-0293, Japan. Electronic address: s-mori@dokkyomed.ac.jp. 2. Department of Gastroenterological Surgery, Dokkyo Medical University, 880 Kitakobayashi, Mibu, Shimotsuga, Tochigi 321-0293, Japan.
Abstract
BACKGROUND: We investigated whether a preoperative scoring system (the "CRP-AFP Score [CAS]") based on the serum levels of C-reactive protein and alpha-fetoprotein would predict outcome in patients undergoing hepatectomy for hepatocellular carcinoma. METHODS: The CAS was defined as follows: patients with an elevated level of both C-reactive protein (>.3 mg/dL) and alpha-fetoprotein (>20 ng/mL) were assigned a score of 2, and patients showing one or none of these abnormalities were assigned a score of 1 or 0, respectively. RESULTS: A total of 349 patients were identified. Pathologic findings, in terms of tumor size, histologic grade, vascular invasion, intrahepatic metastasis, and recurrence rate, worsened as the CAS increased. CAS 2 patients had a poorer 5-year overall survival than CAS 0 or 1 patients (32.2% vs 59.7% vs 49.2%, respectively; P < .001). CONCLUSIONS: The CAS is an informative scoring system that can predict outcome in patients with hepatocellular carcinoma after hepatectomy.
BACKGROUND: We investigated whether a preoperative scoring system (the "CRP-AFP Score [CAS]") based on the serum levels of C-reactive protein and alpha-fetoprotein would predict outcome in patients undergoing hepatectomy for hepatocellular carcinoma. METHODS: The CAS was defined as follows: patients with an elevated level of both C-reactive protein (>.3 mg/dL) and alpha-fetoprotein (>20 ng/mL) were assigned a score of 2, and patients showing one or none of these abnormalities were assigned a score of 1 or 0, respectively. RESULTS: A total of 349 patients were identified. Pathologic findings, in terms of tumor size, histologic grade, vascular invasion, intrahepatic metastasis, and recurrence rate, worsened as the CAS increased. CAS 2patients had a poorer 5-year overall survival than CAS 0 or 1 patients (32.2% vs 59.7% vs 49.2%, respectively; P < .001). CONCLUSIONS: The CAS is an informative scoring system that can predict outcome in patients with hepatocellular carcinoma after hepatectomy.
Authors: Aasmund Avdem Fretland; Andrey Sokolov; Nadya Postriganova; Airazat M Kazaryan; Soren E Pischke; Per H Nilsson; Ingrid Nygren Rognes; Bjorn Atle Bjornbeth; Morten Wang Fagerland; Tom Eirik Mollnes; Bjorn Edwin Journal: Medicine (Baltimore) Date: 2015-10 Impact factor: 1.817